Checking the Heart for Side Effects of Radiation Treatment in Chest Cancers
Tests imaging and blood markers to predict heart harm in adults with chest cancers.
Plain-language title generated from the registry record
Registry title: Radiation-induced Toxicity of the Heart
Key facts
- Where
- Dresden, GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-small cell lung cancer, esophageal cancer or breast cancer who are due to have radiation therapy, with or without chemotherapy, meant to remove all of the disease.
- Age
- 18 years or older
- Sex
- Men and women can join for lung and esophageal cancer; for breast cancer, only women can join.
- Disease stage
- Non-small cell lung cancer, esophageal cancer or breast cancer, with radiation therapy (with or without chemotherapy) planned to remove all of the disease.
Main reasons for not taking part
- Cannot give consent
- Pregnant women
- Cannot have an MRI scan (for example pacemaker, defibrillator, neurostimulator, aneurysm clips, cochlear implants, permanent make-up, metal splinters or bone implants)
- Poor kidney function (GFR below 30 ml/min)
- Treatment is only meant to ease symptoms (palliative)
Read by machine on 12 November 2026.
Where in Germany
- University of Technology, University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation OncologyDresden, GermanyContact: Esther G. C. Troost, Prof. Dr. med. Dr.No longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Technische Universität Dresden
- Trial code
- NCT06986291
- Record updated
- 29 May 2025
- Original description
Late side effects in radio(chemo)therapy [R(CH)T] pose a critical limitation to patients' overall survival and quality of life. Even though toxicities of the heart are highly relevant for patients with cancer in the thoracic region, risk stratification models for these toxicities are lacking. In this study, liquid, functional and imaging biomarkers are being investigated for their use in prediction of cardiac toxicity following R(CH)T for patients with thoracic malignancies.Read full original descriptionShow less
Quantitative Assessment of Radiation-induced Toxicity of the Heart
Late side effects in radio(chemo)therapy [R(CH)T] pose a critical limitation to patients' overall survival and quality of life. Even though toxicities of the heart are highly relevant for patients with cancer in the thoracic region, risk stratification models for these toxicities are lacking. In this study, liquid, functional and imaging biomarkers are being investigated for their use in prediction of cardiac toxicity following R(CH)T for patients with thoracic malignancies.
Inclusion: Patients 18 years old or older; Patient's consent and written consent is available; Patients with the non-small cell lung cancer or esophageal cancer or breast cancer who have an indication for intended curative radio(chemo)therapy (in the case of breast cancer inclusion of female patients only).
Exclusion: Patients with contraindications for MRI examinations (pacemakers, defibrillators, neurostimulators, aneurysm clips, cochlear implants, permanent make-up, metal splinters or osseosynthetic implants); Patients with insufficient kidney function (glomerular filtration rate (GFR) of less than 30 ml/min); Patients who are not capable of giving consent; Pregnant women; Patients with the aforementioned tumour entities for whom a palliative indication exists.